LEGN Legend Biotech USA Inc.
Price Chart
Executive Summary
Legend Biotech presented first-in-human proof-of-concept data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, at EHA 2026. At the higher dose level (DL2), 6/6 patients achieved objective responses and 5/6 achieved complete responses with no serious adverse events or deaths, supporting a potential paradigm shift in cell therapy delivery.
Actionable Insight
This is an early but highly promising proof-of-concept for in vivo CAR-T, a novel modality that could disrupt the cell therapy landscape. Monitor for Phase 2 dose selection and expansion data; the lack of lymphodepletion and favorable safety profile differentiate LB2501 from current CAR-T therapies. Near-term catalyst: next clinical update or regulatory interaction.
Key Facts
- LB2501 achieved 100% ORR (6/6) and 83.3% CR rate (5/6) at dose level 2 in R/R B-NHL patients
- No dose-limiting toxicities, serious adverse events, ICANS, or deaths reported across 12 patients
- In vivo CAR-T generation without lymphodepletion — potential to simplify treatment and expand access
- Data presented in late-breaking session at EHA 2026 Congress (Abstract #LB5006)
- All responses at DL2 were ongoing at data cutoff; CAR-T cells detectable up to 116 days
Financial Impact
Early-stage proof-of-concept; no revenue or deal value disclosed. LB2501 is investigational with no approved status.
Risk Factors
- Phase 1 data in only 12 patients — small sample size limits generalizability
- In vivo CAR-T is unproven at scale; manufacturing and durability unknowns remain
- Competition from other in vivo CAR-T programs (e.g., Umoja, Sana) and approved ex vivo CAR-Ts
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311435 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 14, 2026
1d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
Jun 2, 2026
12d ago
|
6-K
| $36.28 $35.98 | ▼ −0.83% | ▼ −0.13% | $35.87 (−1.13%) |
|
Jun 2, 2026
12d ago
|
Press Release
| $36.28 $35.98 | ▼ −0.83% | ▼ −0.13% | $35.87 (−1.13%) |
|
Jun 1, 2026
13d ago
|
6-K
| $25.51 $36.28 | ▲ +42.22% | ▲ +42.07% | $35.87 (+40.61%) |
|
Jun 1, 2026
13d ago
|
Press Release
| $25.51 $36.28 | ▲ +42.22% | ▲ +42.07% | $35.87 (+40.61%) |
|
May 21, 2026
24d ago
|
6-K
| $29.37 $29.53 | ▲ +0.54% | ▼ −0.04% | $35.87 (+22.13%) |
|
May 21, 2026
24d ago
|
Press Release
| $29.37 $29.53 | ▲ +0.54% | ▼ −0.04% | $35.87 (+22.13%) |
|
May 12, 2026
4w ago
|
6-K
| $28.26 $28.67 | ▲ +1.45% | ▲ +0.88% | $35.87 (+26.93%) |
|
May 12, 2026
4w ago
|
Press Release
| $28.26 $28.67 | ▲ +1.45% | ▲ +0.88% | $35.87 (+26.93%) |
|
Apr 28, 2026
6w ago
|
Press Release
| $23.56 $22.77 | ▼ −3.35% | ▼ −3.34% | $35.87 (+52.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access